Collin Ball
Foot & Ankle Surgery · London, KYNPI 1619166378
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,359 of the $6,043 with a category attached, or 88.7%. 27 manufacturers reported payments, led by Smith+Nephew at 45.7% of the total. Reporting peaked in 2019 at $1,880 and has fallen 56.5% since, to $817 in 2025.
Across 250 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$3K
- Paratek Pharmaceuticals, Inc.$648
- Averitas Pharma Inc.$538
- Osiris Therapeutics Inc.$341
- Acumed LLC$340
- Integra Lifesciences Corporation$293
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$5008%
- Travel & lodging$1853%
- Food & beverage$5,35989%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 90 | $2,763 |
| Paratek Pharmaceuticals, Inc. | 51 | $648 |
| Averitas Pharma Inc. | 36 | $538 |
| Osiris Therapeutics Inc. | 15 | $341 |
| Acumed LLC | 5 | $340 |
| Integra Lifesciences Corporation | 4 | $293 |
| Abbott | 6 | $250 |
| AbbVie | 11 | $207 |
| Stryker(2 entities) | 4 | $118 |
| Vertex | 4 | $92 |
| Zimmer Biomet | 2 | $71 |
| Melinta Therapeutics, LLC | 3 | $47 |
| Paragon 28, Inc. | 2 | $41 |
| Linvatec Corporation | 1 | $39 |
| Treace Medical Concepts, Inc. | 2 | $34 |
| Bioventus LLC | 2 | $29 |
| Pacira Therapeutics, Inc. | 2 | $25 |
| Orthofix Medical, Inc. | 1 | $23 |
| Sanara Medtech Inc. | 1 | $19 |
| Kerecis Limited | 1 | $19 |
| My01 Inc. | 1 | $18 |
| Hartmann USA, Inc. | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Davol Inc. | 1 | $16 |
| Solventum Corporation | 1 | $16 |
| Avanos Medical | 1 | $13 |
| Organogenesis Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,043 in reported general payments places this provider in the 65th percentile of 141 foot & ankle surgery providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 26 | $207,701 |
| QutenzaCapsaicin/Skin Cleanser | 38 | $138,661 |
| Tobramycin Sulfate | 23 | $66,457 |
| ErtapenemErtapenem Sodium | 22 | $18,012 |
| Vancomycin Hcl | 36 | $8,588 |
| Pregabalin | 286 | $7,123 |
| Gabapentin | 610 | $5,824 |
| Linezolid | 20 | $5,577 |
| Voriconazole | 19 | $4,652 |
| Diclofenac Sodium | 150 | $4,371 |
| Itraconazole | 26 | $2,414 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 28 | $1,796 |
| Duloxetine Hcl | 31 | $1,536 |
| Ammonium Lactate | 82 | $1,524 |
| Neomycin Sulfate | 41 | $1,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Paratek Pharmaceuticals, Inc.Nuzyra | $648 | $207,70126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 141 foot & ankle surgery providers in Kentucky.
Other foot & ankle surgery in London
- William Adams IiPaducah$485K
- Sofie PinneyCynthiana$130K
- Carl KihmLouisville$89K
- Bradford FineLexington$82K
- Nicholas LacoLouisville$60K
- Jay LechnerLouisville$29K
- Russell BakerCarrollton$27K
- William McGloneLouisville$26K
- Timothy FordLouisville$26K
- Garrett WiremanLouisville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.